^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MSH2 mutation

    i
    Other names: MSH2, MutS Homolog 2, HMSH2, MutS (E. Coli) Homolog 2, MutS Homolog 2, Nonpolyposis Type 1, DNA Mismatch Repair Protein Msh2, MutS Protein Homolog 2, HNPCC1, HNPCC, LCFS2, COCA1, FCC1
    Entrez ID:
    4436
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Apply
    Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes (NCT02371135)
    Phase N/A
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    02/01/2015
    Primary completion :
    02/01/2026
    Completion :
    02/01/2026
    STK11 • MLH1 • MSH6 • MSH2 • SMAD4 • APC • EPCAM • BMPR1A
    |
    MSH2 mutation • MLH1 mutation • PMS2 mutation
    Researching the Effect of Aerobic Exercise on Cancer (NCT03996239)
    Phase N/A
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    06/14/2024
    Initiation :
    06/20/2019
    Primary completion :
    06/01/2024
    Completion :
    06/01/2024
    MLH1 • MSH6 • MSH2 • EPCAM
    |
    MSH2 mutation • MLH1 mutation • PMS2 mutation
    Atorvastatin ± Aspirin in Lynch Syndrome Syndrome (NCT04379999)
    Phase 1
    Fox Chase Cancer Center
    Recruiting
    Last update posted :
    06/13/2024
    Initiation :
    09/10/2018
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    MLH1 • MSH6 • MSH2 • EPCAM • CASP3
    |
    MSH2 mutation • MLH1 mutation • PMS2 mutation
    |
    atorvastatin
    Pancreatic Cancer Early Detection Program (PCEDP) (NCT02206360)
    Phase N/A
    White Plains Hospital
    Active, not recruiting
    Last update posted :
    05/24/2024
    Initiation :
    04/01/2014
    Primary completion :
    03/01/2024
    Completion :
    06/01/2024
    BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1
    |
    TP53 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation
    Quebec Pancreas Cancer Study (QPCS) (NCT04104230)
    Phase N/A
    George Zogopoulos
    Recruiting
    Last update posted :
    04/17/2024
    Initiation :
    03/12/2012
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1
    |
    ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation
    A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals (NCT03250078)
    Phase N/A
    Nuvance Health
    Recruiting
    Last update posted :
    04/01/2024
    Initiation :
    11/01/2016
    Primary completion :
    11/01/2026
    Completion :
    11/01/2026
    BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2
    |
    BRCA1 mutation • ATM mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • PMS2 mutation
    A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome (NCT05411718)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    03/13/2024
    Initiation :
    03/21/2023
    Primary completion :
    11/30/2025
    Completion :
    11/30/2025
    MSI • MLH1 • MSH6 • MSH2
    |
    MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation
    |
    aspirin
    GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study (NCT03751761)
    Phase 1/2
    Asan Medical Center
    Completed
    Last update posted :
    02/28/2024
    Initiation :
    06/11/2018
    Primary completion :
    08/30/2023
    Completion :
    08/30/2023
    PD-L1 • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3 • PMS1 • POLD2
    |
    MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PD-L1 amplification • POLD1 mutation • MSH3 mutation • PMS2 mutation • MLH3 mutation • PMS1 mutation • POLD2 mutation
    |
    Imfinzi (durvalumab) • paclitaxel • Imjudo (tremelimumab-actl)
    Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention (NCT05677048)
    Phase N/A
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/28/2024
    Initiation :
    04/14/2023
    Primary completion :
    10/31/2025
    Completion :
    10/31/2027
    BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • EPCAM
    |
    BRCA1 mutation • MSH2 mutation • PMS2 mutation
    Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients, CORAL Study (NCT05410977)
    Phase N/A
    Mayo Clinic
    Recruiting
    Last update posted :
    01/18/2024
    Initiation :
    03/30/2022
    Primary completion :
    04/01/2025
    Completion :
    04/01/2026
    MLH1 • MSH6 • MSH2 • EPCAM
    |
    MSH2 mutation • MLH1 mutation • PMS2 mutation
    Cycling in Preventing Colorectal Cancer in Participants With Lynch Syndrome (NCT03495674)
    Phase N/A
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    01/05/2024
    Initiation :
    04/04/2018
    Primary completion :
    01/02/2024
    Completion :
    01/02/2024
    MSI • MLH1 • MSH6 • MSH2 • EPCAM
    |
    MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation